



March 6th, 2018

This memo will confirm the participation of Vestra Clinics sro in Axovant's MINDSET study that compared RVT-101 35 mg to placebo in patients with mild to moderate Alzheimer's disease. The Principal Investigator was Dr. Ladislav Pazdera.

Dr. Pazdera and his team were the highest enrolling site of the five sites in the Czech Republic, the 2nd highest enrolling site in the EU, and the 3rd highest enrolling site in the study globally. The team successfully screened 31 patients for participation in the study, and randomized 27 patients. This represented 40% of all patients screened in the Czech Republic, and 47% of all patients randomized in the country. Dr. Pazdera had a very low screen failure rate of only 13%, and all randomized patients completed the trial, compared to a nearly 40% screenfail rate overall.

A total of 177 sites screened 2173 patients and enrolled 1315 patients in 19 countries around the world. Dr. Pazdera's site met all timelines, and was a significant contributor to the study. He was audited by Axovant, and had no critical and no major findings.

A handwritten signature in black ink, appearing to read "Shari Coslett". The signature is fluid and cursive, with a long, sweeping line extending from the end.

Shari Coslett
Vice President Clinical Operations
Axovant Sciences Inc.
11 Times Square, 33rd Floor
New York, NY 10036